CXCL10 and cutaneous leishmaniasis: Recent findings point to CXCL-10 (C-X-C motif chemokine 10) as a potential tool for immunotherapy of cutaneous leishmaniasis, since this molecule favors a shift towards a Th1 pro-inflammatory response [81].